Next-Generation Burn Care Program
Severe Burns
Research/PreclinicalActive
Key Facts
About Vericel
Vericel is a revenue-generating biopharmaceutical company with a mission to provide life-enhancing cell therapies for serious medical conditions in sports medicine and burn care. The company has achieved significant commercial success with its FDA-approved products MACI (for knee cartilage defects) and Epicel (for severe burns), and has expanded its portfolio through the North American licensing of NexoBrid® for burn eschar removal. Its strategy centers on deepening market penetration for its commercial products, pursuing label expansions, and leveraging its proprietary autologous cell therapy manufacturing platform to address adjacent high-need therapeutic areas.
View full company profile